Faderl S - Search Results

1

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.

Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, Kantarjian HM. Giles FJ, et al. Among authors: faderl s. Leuk Res. 2003 Dec;27(12):1091-6. doi: 10.1016/s0145-2126(03)00094-8. Leuk Res. 2003. PMID: 12921945 Clinical Trial.

2

Chronic myelogenous leukemia: update on biology and treatment.

Faderl S, Kantarjian HM, Talpaz M. Faderl S, et al. Oncology (Williston Park). 1999 Feb;13(2):169-80; discussion 181, 184. Oncology (Williston Park). 1999. PMID: 10079468 Free article. Review.

3

Shift of immunoglobulin phenotypes in B-cell precursor cell lines.

Faderl S, Estrov Z. Faderl S, et al. Leuk Res. 2002 Jan;26(1):11-2. doi: 10.1016/s0145-2126(01)00089-3. Leuk Res. 2002. PMID: 11734298

4

Central nervous system relapse in adults with acute lymphoblastic leukemia.

Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C, Faderl S, Kantarjian H. Surapaneni UR, et al. Among authors: faderl s. Cancer. 2002 Feb 1;94(3):773-9. doi: 10.1002/cncr.10265. Cancer. 2002. PMID: 11857312 Free article.

5

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.

Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S, Kantarjian H. Cortes J, et al. Among authors: faderl s. Cancer. 2002 Mar 1;94(5):1492-9. doi: 10.1002/cncr.10365. Cancer. 2002. PMID: 11920506 Free article. Clinical Trial.

6

Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia.

Verstovsek S, Kantarjian H, Manshouri T, O'Brien S, Faderl S, Talpaz M, Cortes J, Albitar M. Verstovsek S, et al. Among authors: faderl s. Cancer. 2002 Mar 1;94(5):1517-21. doi: 10.1002/cncr.10363. Cancer. 2002. PMID: 11920509 Free article.

7

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.

O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. O'Brien S, et al. Among authors: faderl s. Cancer. 2002 Apr 1;94(7):2024-32. doi: 10.1002/cncr.10436. Cancer. 2002. PMID: 11932905 Free article.

8

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.

Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M. Kantarjian HM, et al. Among authors: faderl s. Blood. 2002 May 15;99(10):3547-53. doi: 10.1182/blood.v99.10.3547. Blood. 2002. PMID: 11986206 Free article. Clinical Trial.

9

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.

Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S, Kantarjian HM. Ravandi F, et al. Among authors: faderl s. Leuk Res. 2002 Jul;26(7):643-9. doi: 10.1016/s0145-2126(01)00188-6. Leuk Res. 2002. PMID: 12008081

10

Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission.

Faderl S, Thall PF, Kantarjian HM, Estrov Z. Faderl S, et al. Br J Haematol. 2002 Jun;117(4):869-74. doi: 10.1046/j.1365-2141.2002.03506.x. Br J Haematol. 2002. PMID: 12060122 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

387 results

Search Page

Filters